A cloud merger now decides CHRN
- The main story is no longer just exoskeletons, it is the Applied Digital Cloud business combination.
- If the deal closes, the contributor is expected to own about 97% of the combined company.
- The legacy business still has a real Medicare angle, with CMS payment near $91,000 for Ekso Indego Personal.
- As of March 31, 2026, management said cash on hand should fund operations into the early part of the third quarter of 2026.
- Management also warned that without the deal, there is no reasonable near-term path to profit or positive cash flow.
The deal is the stock
CHRN is now a binary story. The legacy company makes robotic exoskeletons for rehab clinics, home use, and industrial work. But the investment case has moved to the planned Applied Digital Cloud transaction signed on February 15, 2026.
If the business combination closes, Applied Digital Cloud becomes a wholly owned subsidiary, the company changes its name to ChronoScale Corporation, and the contributor is expected to own about 97% of the combined company. That means current holders are really betting on the deal closing and on the value of the new cloud business, not only on the old exoskeleton lineup.
The remaining bull case for the old business is not zero. CMS approved a payment level of about $91,000 for Ekso Indego Personal, and the company said it had over 50 people it believed could qualify for potential reimbursement as of March 31, 2026. If claims start moving faster, Personal Health could finally add more revenue.
The bear case is blunt. In the Q1 2026 filing, management said that absent the business combination, it does not believe there is a reasonable prospect for the business to reach or sustain profit or positive cash flow in the near term without major new capital. If funding is not available, the company said it may need to liquidate assets, seek bankruptcy protection, or wind down operations.
Devices today, cloud if closed
The legacy business designs, develops, and sells exoskeleton and related rehab products. It sells devices, service and support, subscriptions, parts, and other items. In Q1 2026, revenue was $2.141 million, down 37% from Q1 2025, mainly because Enterprise Health device sales fell across the Americas, EMEA, and APAC.
Enterprise Health is the main source of sales. It includes EksoNR and Ekso Indego Therapy for neurorehab clinics, plus EVO for industrial worker safety. These are large capital purchases, so orders can be lumpy and slow.
Personal Health sells Ekso Indego Personal to individuals, mainly people with spinal cord injury. The company works through DME and O&P partners, but Medicare claims have often gone through appeals. That slows cash collection and makes the sales ramp harder to predict.
The business model breaks if the merger fails and financing does not arrive. The company had about $3.7 million of effective unrestricted cash as of March 31, 2026, after restricted cash, and used $2.123 million of cash in operations during Q1 2026. That is why closing conditions and cash runway matter more than normal product updates right now.
What the old company sells
EksoNR
EksoNR is a robotic exoskeleton used in clinical rehab for patients with conditions such as stroke, brain injury, multiple sclerosis, and spinal cord injury. It sits inside Enterprise Health and depends on clinic budget cycles.
Ekso Indego Therapy
Ekso Indego Therapy is another clinical rehab device. It came from the Human Motion Control acquisition and is sold to rehab providers.
Ekso Indego Personal
Ekso Indego Personal is for individual users in home and community settings, especially people with spinal cord injury. CMS approved a payment level of about $91,000, but many claims have needed appeals.
EVO
EVO is an industrial wearable product for workers doing repeated overhead tasks. It targets injury prevention and fatigue reduction in areas such as aerospace, automotive, manufacturing, and construction trades.
Ekso Nomad
Ekso Nomad is a powered knee ankle foot orthosis. It is currently sold in limited volumes for use in a non-company-sponsored clinical study, with general commercialization expected in late 2026.
MediTouch BalanceTutor
BalanceTutor is a rehab system sold under an exclusive distribution agreement with MediTouch. The company expected sales and distribution to begin in the second quarter of 2026.
One segment, several revenue lines
The company reports one operating and reportable segment, with Enterprise Health and Personal Health as target markets. Because the Q1 2026 filing did not give a revenue split by those markets, the structured mix uses Q1 2026 revenue by major source.
What can go wrong
Applied Digital Cloud deal fails
High impact · Medium oddsThis is the biggest risk. The company says the business combination was expected in the second quarter of 2026, but closing depends on approvals, cash conditions, a Nasdaq listing application, consents, and a concurrent private placement. If it fails, management says the standalone business has no reasonable near-term path to profit or positive cash flow without major capital.
Cash runs out before a fix
High impact · High oddsAs of March 31, 2026, effective unrestricted cash was about $3.7 million. Management said cash on hand should fund operations into the early part of the third quarter of 2026, and substantial doubt exists about the company as a going concern. More financing could be highly dilutive.
Legacy holders get heavily diluted
High impact · High oddsIf the business combination closes, the contributor is expected to own about 97% of the combined company before other related transactions. Legacy holders would own a small piece of a different business. That may still work if the cloud business is valuable, but the old exoskeleton upside would be greatly diluted.
Medicare claims stay stuck in appeals
Medium impact · Medium oddsThe Ekso Indego Personal opportunity depends on CMS reimbursement working in practice, not only on the payment level. The company said most reimbursements to date have involved an appeals process. A slow claims process can delay revenue and hurt partner interest.
Enterprise Health orders stay lumpy
Medium impact · High oddsEnterprise Health sales are large purchases for clinics and institutions. In Q1 2026, revenue fell 37% year over year, mainly because Enterprise Health device volume was lower across all regions. A few delayed orders can swing results a lot.